INmune Bio Inc.

Stand

by, your program is about to begin. Greetings and welcome to the Immune Bio Second Quarter 2025 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. You may register to ask a question at any time by pressing star one on your touchtone phone. You may withdraw yourself in the queue by pressing star two. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call. At this time, it is my pleasure to introduce Mr. Daniel Carlson, Head of Investor Relations at ImmuneBio. Daniel.

Thank you, operator, and good afternoon, everyone. We thank you for joining us for the call for ImmuneBio's Second Quarter 2025 financial results. Presenting on today's call are David Moss, co-founder and CEO, Dr. CJ Barnum, Head of Neuroscience, and Dr. Mark Lodell, Chief Scientific Officer and co-founder of ImmuneBio. Before we begin, however, I remind everyone that except for statements of historical fact, the statements made by management in responses to questions on this conference call are forward-looking statements under the Safe Harbor Preservisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ material from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filings with the SEC. There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change. Except as required by law, ImmuneBio disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. Now it's my pleasure to turn the call over to our CEO. David?